Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/S2213-8587(21)00180-7 http://scihub22266oqcxt.onion/10.1016/S2213-8587(21)00180-7 34302745!8294807!34302745     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Lancet+Diabetes+Endocrinol 2021 ; 9 (9): 586-594 Nephropedia Template TP {{tp|p=34302745|t=2021. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial |pdf=|usr=}}{{34302745}} gab.com Text Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial JO: Lancet Diabetes Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=34302745 #FOAvip BACKGROUND: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. METHODS: DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients critically ill at screening were excluded. Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days. Dual primary outcomes were assessed in the intention-to-treat population: the outcome of prevention (time to new or worsened organ dysfunction or death), and the hierarchial composite outcome of recovery (change in clinical status by day 30). Safety outcomes, in patients who received at least one study medication dose, included serious adverse events, adverse events leading to discontinuation, and adverse events of interest. This study is registered with ClinicalTrials.gov, NCT04350593. FINDINGS: Between April 22, 2020 and Jan 1, 2021, 1250 patients were randomly assigned with 625 in each group. The primary composite outcome of prevention showed organ dysfunction or death occurred in 70 patients (11.2%) in the dapagliflozin group, and 86 (13.8%) in the placebo group (hazard ratio [HR] 0.80, 95% CI 0.58-1.10; p=0.17). For the primary outcome of recovery, 547 patients (87.5%) in the dapagliflozin group and 532 (85.1%) in the placebo group showed clinical status improvement, although this was not statistically significant (win ratio 1.09, 95% CI 0.97-1.22; p=0.14). There were 41 deaths (6.6%) in the dapagliflozin group, and 54 (8.6%) in the placebo group (HR 0.77, 95% CI 0.52-1.16). Serious adverse events were reported in 65 (10.6%) of 613 patients treated with dapagliflozin and in 82 (13.3%) of 616 patients given the placebo. INTERPRETATION: In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. FUNDING: AstraZeneca. Twit Text FOAVip Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial ????Lancet Diabetes Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=34302745 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34302745 #FOAvip English Wikipedia <ref>{{Cite pmid|34302745}}</ref> Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial #MMPMID34302745 Kosiborod MN; Esterline R; Furtado RHM; Oscarsson J; Gasparyan SB; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Buenconsejo J; Langkilde AM; Ambery P; Tang F; Gosch K; Windsor SL; Akin EE; Soares RVP; Moia DDF; Aboudara M; Hoffmann Filho CR; Feitosa ADM; Fonseca A; Garla V; Gordon RA; Javaheri A; Jaeger CP; Leaes PE; Nassif M; Pursley M; Silveira FS; Barroso WKS; Lazcano Soto JR; Nigro Maia L; Berwanger O Lancet Diabetes Endocrinol 2021[Sep]; 9 (9): 586-594 PMID34302745show ga BACKGROUND: COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has significant protective benefits for the heart and kidney. We aimed to see whether this agent might provide organ protection in patients with COVID-19 by affecting processes dysregulated during acute illness. METHODS: DARE-19 was a randomised, double-blind, placebo-controlled trial of patients hospitalised with COVID-19 and with at least one cardiometabolic risk factor (ie, hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease). Patients critically ill at screening were excluded. Patients were randomly assigned 1:1 to dapagliflozin (10 mg daily orally) or matched placebo for 30 days. Dual primary outcomes were assessed in the intention-to-treat population: the outcome of prevention (time to new or worsened organ dysfunction or death), and the hierarchial composite outcome of recovery (change in clinical status by day 30). Safety outcomes, in patients who received at least one study medication dose, included serious adverse events, adverse events leading to discontinuation, and adverse events of interest. This study is registered with ClinicalTrials.gov, NCT04350593. FINDINGS: Between April 22, 2020 and Jan 1, 2021, 1250 patients were randomly assigned with 625 in each group. The primary composite outcome of prevention showed organ dysfunction or death occurred in 70 patients (11.2%) in the dapagliflozin group, and 86 (13.8%) in the placebo group (hazard ratio [HR] 0.80, 95% CI 0.58-1.10; p=0.17). For the primary outcome of recovery, 547 patients (87.5%) in the dapagliflozin group and 532 (85.1%) in the placebo group showed clinical status improvement, although this was not statistically significant (win ratio 1.09, 95% CI 0.97-1.22; p=0.14). There were 41 deaths (6.6%) in the dapagliflozin group, and 54 (8.6%) in the placebo group (HR 0.77, 95% CI 0.52-1.16). Serious adverse events were reported in 65 (10.6%) of 613 patients treated with dapagliflozin and in 82 (13.3%) of 616 patients given the placebo. INTERPRETATION: In patients with cardiometabolic risk factors who were hospitalised with COVID-19, treatment with dapagliflozin did not result in a statistically significant risk reduction in organ dysfunction or death, or improvement in clinical recovery, but was well tolerated. FUNDING: AstraZeneca. |*Cardiometabolic Risk Factors[MESH] |Aged[MESH] |Benzhydryl Compounds/*administration & dosage[MESH] |COVID-19/*complications[MESH] |Double-Blind Method[MESH] |Female[MESH] |Glucosides/*administration & dosage[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Multiple Organ Failure/complications/*prevention & control[MESH] |Sodium-Glucose Transporter 2 Inhibitors/*administration & dosage[MESH]Dapagliflozin in patients with cardiometabolic risk factors hospitalis(epmc).pdf DeepDyve Pubget Overpricing